Table 2.
Antitumor activity in ≥ second-line patients
| Investigator Assessment (N=57) |
Independent Assessment (N=57) |
|
|---|---|---|
|
| ||
| Best response, n (%) | ||
| Complete response (CR) | 2 (3·5) | 0 |
| Partial response (PR) | 34 (59·6) | 36 (63·2) |
| Stable disease (SD) | 9 (15·8) | 4 (7·0) |
| Progressive disease (PD) | 7 (12·3) | 8 (14·0) |
| Non-CR/non-PD | 0 | 3 (5·3) |
| Not evaluable | 5 (8·8) | 6 (10·5) |
|
| ||
| Overall response (CR + PR), n (%) [95% CI] | 36 (63·2) [49·3–75·6] | 36 (63·2) [49·3–75·6] |
|
| ||
| Disease control rate (CR + PR + SD), n (%) [95% CI] | 45 (78·9) [66·1–88·6] | 43 (75·4) [62·2–85·9] |
|
| ||
| Progression-free survival, median (95% CI), months | 9·7 (6·9–19·6) | 8·6 (5·2–19·1) |
|
| ||
| Duration of response, median (95% CI), months | 9·0 (6·9–18·3) | 9·0 (5·8–17·6) |